ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not!
Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany gerd.heusch@uk-essen.de.
Gerd
G
Heusch
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA.
Bernard J
BJ
Gersh
D018686:Anesthetics, Intravenous; D015415:Biomarkers / Q000378:metabolism; D002316:Cardiotonic Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D006324:Heart Arrest, Induced / Q000379:methods; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D015337:Multicenter Studies as Topic; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D015742:Propofol; D019210:Troponin I / Q000378:metabolism
D018686:Anesthetics, Intravenous; D015415:Biomarkers; D002316:Cardiotonic Agents; D019210:Troponin I; D015742:Propofol